Oncolytic Virus Immunotherapy Market Insights Video
According to Cognitive Market Research, the global Oncolytic Virus Immunotherapy market size will be USD 312.5 million in 2024. It will expand at a compound annual growth rate (CAGR) of 22.50% from 2024 to 2031.
North America held the major market share for more than 40% of the global revenue with a market size of USD 125.00 million in 2024 and will grow at a compound annual growth rate (CAGR) of 20.7% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 93.75 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 71.88 million in 2024 and will grow at a compound annual growth rate (CAGR) of 24.5% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 15.63 million in 2024 and will grow at a compound annual growth rate (CAGR) of 21.9% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 6.25 million in 2024 and will grow at a compound annual growth rate (CAGR) of 22.2% from 2024 to 2031.
The Non-small Cell Lung Cancer (NSCLC) category is the fastest growing segment of the Oncolytic Virus Immunotherapy industry
